A new facility type integrates next-generation mobile cleanroom systems.
Facilities for advanced therapies should be configurable to flexibly segregate production for late-stage and commercial multiproduct operation. Efficient design of a flexible and high-containment vaccine manufacturing facility that can meet all the challenges presented by the market requires a design philosophy that includes all the key control concepts: air, people, equipment, product, and liquid and solid waste. This article discusses best practices for such control and describes the use of modular, mobile cleanrooms.
Download the
Vaccine Development and Manufacturing 2017 ebook.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 26–30
When referring to this article, please cite it as T. Page, "Designing and Operating Flexible, High-Containment Vaccine Manufacturing," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.